| Drug General Information |
| Drug ID |
D0U3ZL
|
| Former ID |
DNC006873
|
| Drug Name |
CARBOXYFENTANYL
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C23H28N2O3
|
| Canonical SMILES |
C1CN(CCC1N(C2=CC=CC=C2)C(=O)CCC(=O)O)CCC3=CC=CC=C3
|
| InChI |
1S/C23H28N2O3/c26-22(11-12-23(27)28)25(20-9-5-2-6-10-20)21-14-17-24(18-15-21)16-13-19-7-3-1-4-8-19/h1-10,21H,11-18H2,(H,27,28)
|
| InChIKey |
MEVFKTVEGJUHHI-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Delta-type opioid receptor |
Target Info |
Inhibitor |
[1]
|
|---|
| Mu-type opioid receptor |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04080:Neuroactive ligand-receptor interaction
|
|
Estrogen signaling pathway
|
|
Morphine addiction
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Enkephalin release
|
|
Opioid proenkephalin pathway
|
|
Opioid proopiomelanocortin pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Pathway Interaction Database
|
IL4-mediated signaling events
|
|
Reactome
|
Peptide ligand-binding receptors
|
|
G alpha (i) signalling eventsR-HSA-375276:Peptide ligand-binding receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
GPCRs, Class A Rhodopsin-like
|
|
Peptide GPCRs
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP69:TCR Signaling Pathway
|
|
Opioid Signalling
|
|
GPCR downstream signaling
|
| References |
| REF 1 | J Med Chem. 2007 Nov 1;50(22):5528-32. Epub 2007 Oct 10.Development of novel enkephalin analogues that have enhanced opioid activities at both mu and delta opioid receptors. |
|---|
